Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Sue Leurgans and Christopher Goetz.
Sue Leurgans
Connection Strength
2.952
Christopher Goetz
  1. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.314
  2. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.306
  3. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.269
  4. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.263
  5. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.245
  6. The role of the serotonin system in animal models of myoclonus. Adv Neurol. 2002; 89:244-8.
    View in: PubMed
    Score: 0.198
  7. Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. Mov Disord Clin Pract. 2017 May-Jun; 4(3):412-415.
    View in: PubMed
    Score: 0.139
  8. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.094
  9. Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord. 2009 May 15; 24(7):1070-3.
    View in: PubMed
    Score: 0.083
  10. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.080
  11. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.078
  12. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.077
  13. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.070
  14. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.067
  15. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.067
  16. Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
    View in: PubMed
    Score: 0.066
  17. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
    View in: PubMed
    Score: 0.065
  18. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.065
  19. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.061
  20. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.056
  21. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.054
  22. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
    View in: PubMed
    Score: 0.054
  23. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.052
  24. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.050
  25. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.027
  26. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.021
  27. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.016
  28. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.